On-Demand Webinar

Adaptive Designs for Phase II Trials

Adaptive Designs for Phase II Trials
3:19

Adaptive Designs for Phase II Trials

The cost and time of a Phase II trial can be reduced by using a successful adaptive design.

An adaptive phase II trial design can provide an earlier determination of futility and prediction of phase III success. This reduces the overall phase II and III trial sizes whilst shortening overall drug development time.

You will learn about:

  • Important aspects of Phase II trial designs to consider
  • Practical worked examples of:
    • MCP-Mod (continuous outcome)
    • MCP-Mod (binary outcome)
    • Fleming GST (binary outcome)

nQuery helps make your clinical trials faster, less costly and more successful with tools for sample size calculation - refining Frequentist, Bayesian & Adaptive designs

Start your unlimited 14-day trial to help design efficient, informative and ethical adaptive trials.

 


 

 

 

Who is this for?

This will be highly beneficial if you're a biostatistician, scientist, or clinical trial professional that is involved in sample size calculation and the optimization of clinical trials in:

 

  • Pharma and Biotech
  • CROs
  • Med Device
  • Research Institutes
  • Regulatory Bodies
Share on Twitter
Share on LinkedIn

Get started with nQuery today

Try for free and upgrade as your team grows